ANI Pharmaceuticals Inc (ANIP)
61.98
+0.13
(+0.21%)
USD |
NASDAQ |
Nov 12, 15:00
ANI Pharmaceuticals Revenue (TTM): 555.46M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 555.46M |
| June 30, 2024 | 538.95M |
| March 31, 2024 | 517.46M |
| December 31, 2023 | 486.82M |
| September 30, 2023 | 449.39M |
| June 30, 2023 | 401.39M |
| March 31, 2023 | 358.69M |
| December 31, 2022 | 316.38M |
| September 30, 2022 | 283.08M |
| June 30, 2022 | 251.32M |
| March 31, 2022 | 226.09M |
| December 31, 2021 | 216.14M |
| September 30, 2021 | 212.46M |
| June 30, 2021 | 213.38M |
| March 31, 2021 | 213.22M |
| December 31, 2020 | 208.48M |
| September 30, 2020 | 199.19M |
| June 30, 2020 | 197.55M |
| March 31, 2020 | 203.43M |
| December 31, 2019 | 206.55M |
| September 30, 2019 | 215.70M |
| June 30, 2019 | 215.07M |
| March 31, 2019 | 207.98M |
| December 31, 2018 | 201.58M |
| September 30, 2018 | 191.74M |
| Date | Value |
|---|---|
| June 30, 2018 | 189.20M |
| March 31, 2018 | 186.70M |
| December 31, 2017 | 176.84M |
| September 30, 2017 | 167.76M |
| June 30, 2017 | 158.12M |
| March 31, 2017 | 144.70M |
| December 31, 2016 | 128.62M |
| September 30, 2016 | 108.45M |
| June 30, 2016 | 89.90M |
| March 31, 2016 | 78.08M |
| December 31, 2015 | 76.32M |
| September 30, 2015 | 79.32M |
| June 30, 2015 | 76.74M |
| March 31, 2015 | 63.87M |
| December 31, 2014 | 55.97M |
| September 30, 2014 | 45.46M |
| June 30, 2014 | 35.91M |
| March 31, 2014 | 35.42M |
| December 31, 2013 | 24.66M |
| September 30, 2013 | 16.10M |
| June 30, 2013 | 8.375M |
| March 31, 2013 | 2.332M |
| December 31, 2012 | 2.301M |
| September 30, 2012 | 0.4475M |
| June 30, 2012 | 0.5199M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
197.55M
Minimum
Jun 2020
555.46M
Maximum
Sep 2024
312.77M
Average
238.71M
Median
Revenue (TTM) Benchmarks
| Alimera Sciences Inc | 99.68M |
| Windtree Therapeutics Inc | -- |
| Allogene Therapeutics Inc | -- |
| AIM ImmunoTech Inc | 0.201M |
| Protalix BioTherapeutics Inc | 38.05M |